Page 16 - Read Online

Kovacs et al. Vessel Plus 2018;2:15 I http://dx.doi.org/10.20517/2574-1209.2018.06 Page 7 of 9

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Johnson ER, Matthay MA. Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv 2010;23:243-
52.
Production of TNF-α,CINC-1, IL-1β, IL-6, NO
Expression of ICAM-1, E-selectin and NF-κBp65 2. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung
MPO activation injury. N Engl J Med 2005;353:1685-93.
Lung infiltration of inflammatory cells 3. Butt Y, Kurdowska A, Allen TC. Acute lung injury: a clinical and molecular review. Arch Pathol Lab Med 2016;140:345-50.
Histopathological changes 4. Parekh D, Dancer RC, Thickett DR. Acute lung injury. Clin Med (Lond) 2011;11:615-8.
5. Gonzales JN, Lucas R, Verin AD. The acute respiratory distress syndrome: mechanisms and perspective therapeutic approaches. Austin
J Vasc Med 2015;2:1009.
6. Maniatis NA, Kotanidou A, Catravas JD, Orfanos SE. Endothelial pathomechanisms in acute lung injury. Vascul Pharmacol
2008;49:119-33.
7. Lucas R, Verin AD, Black SM, Catravas JD. Regulators of endothelial and epithelial barrier integrity and function in acute lung injury.
Biochem Pharmacol 2009;77:1763-72.
8. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev
2004;84:869-901.
9. Kasa A, Csortos C, Verin AD. Cytoskeletal mechanisms regulating vascular endothelial barrier function in response to acute lung injury.
Tissue Barriers 2015;3:e974448.
10. Jeffries MA, Sawalha AH. Autoimmune disease in the epigenetic era: how has epigenetics changed our understanding of disease and
how can we expect the field to evolve? Expert Rev Clin Immunol 2015;11:45-58.
11. Greer JM, McCombe PA. The role of epigenetic mechanisms and processes in autoimmune disorders. Biologics 2012;6:307-27.
12. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998;12:599-606.
13. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998;20:615-26.
14. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26:5420-32.
15. Halili MA, Andrews MR, Sweet MJ, Fairlie DP. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem
2009;9:309-19.
16. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone
H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000;20:6891-903.
17. Yang XJ, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 2008;31:449-61.
18. Peng L, Yuan Z, Seto E. Histone deacetylase activity assay. Methods Mol Biol 2015;1288:95-108.
19. Saito S, Lasky JA, Guo W, Nguyen H, Mai A, Danchuk S, Sullivan DE, Shan B. Pharmacological inhibition of HDAC6 attenuates
endothelial barrier dysfunction induced by thrombin. Biochem Biophys Res Commun 2011;408:630-4.
20. Joshi AD, Barabutis N, Birmpas C, Dimitropoulou C, Thangjam G, Cherian-Shaw M, Dennison J, Catravas JD. Histone deacetylase
inhibitors prevent pulmonary endothelial hyperpermeability and acute lung injury by regulating heat shock protein 90 function. Am J
Physiol Lung Cell Mol Physiol 2015;309:L1410-9.
21. Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol 2014;6:a018713.
22. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the
classical HDAC family. Biochem J 2003;370:737-49.
23. Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, Auwerx J. Sirtuins: the ‘magnificent seven’, function, metabolism and
longevity. Ann Med 2007;39:335-45.
24. Sengupta N, Seto E. Regulation of histone deacetylase activities. J Cell Biochem 2004;93:57-67.
25. Bjerling P, Silverstein RA, Thon G, Caudy A, Grewal S, Ekwall K. Functional divergence between histone deacetylases in fission yeast
by distinct cellular localization and in vivo specificity. Mol Cell Biol 2002;22:2170-81.
26. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99.
27. Yang WM, Tsai SC, Wen YD, Fejer G, Seto E. Functional domains of histone deacetylase-3. J Biol Chem 2002;277:9447-54.
28. Van den Wyngaert I, de Vries W, Kremer A, Neefs J, Verhasselt P, Luyten WH, Kass SU. Cloning and characterization of human histone
deacetylase 8. FEBS Lett 2000;478:77-83.
29. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol
2008;9:206-18.
30. Watson PJ, Millard CJ, Riley AM, Robertson NS, Wright LC, Godage HY, Cowley SM, Jamieson AG, Potter BV, Schwabe JW. Insights
into the activation mechanism of class I HDAC complexes by inositol phosphates. Nat Commun 2016;7:11262.
31. Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet 2003;19:286-93.